Prima BioMed is likely to get a boost today after US Dendreon Corp, maker of the prostate-cancer drug Provenge, rose 39 per cent after reporting fourth-quarter revenue more than tripled from a year earlier.
Australian-listed Prima BioMed has developed a similar product to treat ovarian cancer.